Therapeutic Uses of Medical Cannabis: An Overview of its Functions in Disease Management

[1]  E. O. Irokanulo,et al.  Comparative effects of combined use of alcohol with cannabis and tobacco on testicular function in rats. , 2021, Toxicology research.

[2]  K. Müller-Vahl,et al.  Two Decades of the International Association for Cannabinoid Medicines: 20 Years of Supporting Research and Activities Toward the Medicinal Use of Cannabis and Cannabinoids. , 2020, Cannabis and cannabinoid research.

[3]  J. Leite,et al.  The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights , 2020, Neuroscience & Biobehavioral Reviews.

[4]  C. Hughes,et al.  Depenalization, diversion and decriminalization: A realist review and programme theory of alternatives to criminalization for simple drug possession , 2019, European Journal of Criminology.

[5]  E. Altman,et al.  The classification of Cannabis hemp cultivars by thermal desorption direct analysis in real time mass spectrometry (TD-DART-MS) with chemometrics , 2019, Analytical and Bioanalytical Chemistry.

[6]  T. EurichDean,et al.  A Description of the Medical Cannabis Use in Ontario, Canada , 2019, Cannabis and Cannabinoid Research.

[7]  G. Joshi,et al.  A review of the anesthetic implications of marijuana use , 2019, Proceedings.

[8]  Samantha G. Farris,et al.  Vaporization of Marijuana Among Recreational Users: A Qualitative Study. , 2019, Journal of studies on alcohol and drugs.

[9]  H. Bradshaw,et al.  Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure , 2018, Investigative ophthalmology & visual science.

[10]  S. Bhattacharyya,et al.  Cannabis use and the development of tolerance: a systematic review of human evidence , 2018, Neuroscience & Biobehavioral Reviews.

[11]  R. Hancox,et al.  The Case for Cannabinoid CB1 Receptors as a Target for Bronchodilator Therapy for β-agonist Resistant Asthma. , 2018, Current drug targets.

[12]  M. Cole,et al.  Tolerance to hypothermic and antinoceptive effects of ∆9-tetrahydrocannabinol (THC) vapor inhalation in rats , 2018, Pharmacology Biochemistry and Behavior.

[13]  M. Badowski,et al.  Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer , 2018, Therapeutics and clinical risk management.

[14]  J. Jett,et al.  Cannabis Use, Lung Cancer, and Related Issues , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  N. Altunsoy,et al.  Does trait mindfulness level affect quitting cannabis use? A six week follow-up study , 2017 .

[16]  H. Cabral,et al.  Prenatal, perinatal, and adolescent exposure to marijuana: Relationships with aggressive behavior. , 2016, Neurotoxicology and teratology.

[17]  G. Tanda.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg , 2016, Psychopharmacology.

[18]  M. Schäfer,et al.  Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews , 2016, Der Schmerz.

[19]  A. Altun,et al.  Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists , 2015, The Journal of Physiological Sciences.

[20]  Raphael Mechoulam,et al.  Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder , 2014, Clinical Drug Investigation.

[21]  E. Heerdink,et al.  The prevalence and incidence of medicinal cannabis on prescription in The Netherlands , 2013, European Journal of Clinical Pharmacology.

[22]  M. Fallon,et al.  Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. , 2012, The journal of pain : official journal of the American Pain Society.

[23]  C. Pozzilli,et al.  A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis , 2011, European journal of neurology.

[24]  P. McGuire,et al.  Cannabis and anxiety: a critical review of the evidence , 2009, Human psychopharmacology.

[25]  Jason W Small,et al.  Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. , 2008, Journal of psychiatric research.

[26]  K. Ethans,et al.  Nabilone for the treatment of pain in fibromyalgia. , 2008, The journal of pain : official journal of the American Pain Society.

[27]  Y. Lecrubier,et al.  ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder , 2004, European Neuropsychopharmacology.

[28]  S. Goldberg,et al.  Cannabinoids: reward, dependence, and underlying neurochemical mechanisms—a review of recent preclinical data , 2003, Psychopharmacology.

[29]  H. Emrich,et al.  Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. , 2003, The Journal of clinical psychiatry.

[30]  M. Liebowitz,et al.  Pharmacotherapy of social anxiety disorder , 2002, Biological Psychiatry.

[31]  L. Grinspoon.  On the pharmaceuticalization of marijuana , 2001 .